Meeting
2017 ASCO Annual Meeting
A phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in metastatic colorectal cancer.
Authors
Antoine Hollebecque
Drug Development Department (DITEP), Gustave Roussy, Villejuif, France
Antoine Hollebecque , Guillem Argiles , Thierry Andre , Andres Cervantes , Catherine Leger , Aude Valette , Nadia Amellal , Ronan Fougeray , Josep Tabernero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT02848443
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS3626)
DOI
10.1200/JCO.2017.35.15_suppl.TPS3626
Abstract #
TPS3626
Poster Bd #
245a
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Phase I multicenter, open-label study to establish the maximum tolerated dose (MTD) of trifluridine/tipiracil (TAS-102) and oxaliplatin combination in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Antoine Hollebecque
Poster
2020 Gastrointestinal Cancers Symposium
Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab: Results of the expansion part of a phase I study in patients with metastatic colorectal cancer.
First Author: Roberto Bordonaro
Poster
2018 ASCO Annual Meeting
A phase I expansion study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) and bevacizumab (BEV) in patients with metastatic colorectal cancer (mCRC).
First Author: Anna M. Varghese
Poster
2016 ASCO Annual Meeting
A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
First Author: May Thet Cho